journal article·2025-11Open access

eIF4E Enriched Extracellular Vesicles Induce Immunosuppressive Macrophages through HMGCR‐Mediated Metabolic Rewiring

Sonam Mittal, Minal Nenwani, Ishaque Pulikkal Kadamberi, Sudhir Kumar, Olamide Animasahun, Jasmine George, Shirng‐Wern Tsaih, Prachi Gupta, Mona Singh, Anjali Geethadevi, Chandrima Dey, Noah Meurs, Ajay Shankaran, Pradeep Chaluvally Raghavan, Deepak Nagrath, Sunila Pradeep

Advanced Science· Volume 12· Issue 42

Abstract

Abstract Tumor driven immune suppression poses a significant impediment to the success of immunotherapy in ovarian cancer. Among the various mechanisms contributing to immune suppression, intracellular communication facilitated by tumor‐derived extracellular vesicles (EVs) within the tumor microenvironment emerges as a pivotal factor influencing tumor growth. Here, it is demonstrated that extracellular vesicle‐packaged eIF4E from tumor cells alters protein translation in macrophages, contributing to antitumor immune response. Mechanistically, tumor derived EV‐packaged eIF4E significantly enhances the expression of 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase (HMGCR), driving the synthesis and secretion of cholesterol. This, in turn, activates macrophages and causes immunosuppression through the X‐box binding protein 1 and Programmed death‐ligand 1 (XBP1/PD‐L1) axis. Strikingly, both genetic and pharmacological depletion of HMGCR in macrophages effectively restores their antitumor activity. Clinically, elevated HMGCR expression in tumor‐associated macrophages is associated with poor survival outcomes in ovarian cancer patients. The pivotal role of eIF4E is underscored here as a key signaling mediator, facilitating the communication between tumor and immune cells via EVs to promote immune suppression and suggesting HMGCR as a potential therapeutic target for tumor immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Adenosine and Purinergic Signaling

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Obstetrics and Gynecology Medical College of Wisconsin Milwaukee WI 53226 USA

Department of Biomedical Engineering University of Michigan Ann Arbor MI 48109 USA

Laboratory for Systems Biology of Human Diseases University of Michigan Ann Arbor MI 48109 USA

Department of Microbiology and Immunology Emory University School of Medicine Atlanta Georgia 30322 USA

Department of Chemical Engineering University of Michigan Ann Arbor MI 48109 USA

ECARI Portland Cancer Research Center Portland OR 97239 USA

Medical College of Wisconsin Cancer Center Medical College of Wisconsin Milwaukee WI 53226 USA

Department of Physiology Medical College of Wisconsin Milwaukee WI 53226 USA

Rogel Cancer Center University of Michigan Ann Arbor MI 48106 USA

Funding

Ovarian Cancer Research Fund · National Cancer Institute · U.S. Department of Defense

References (75)

Show source-provided references
1. 10.3390/cancers1212356310.3390/cancers12123563 ↗
2. 10.1002/advs.20210445210.1002/advs.202104452 ↗
3. 10.2174/011568009628190623121305542210.2174/0115680096281906231213055422 ↗
4. 10.1007/s00018-017-2595-910.1007/s00018-017-2595-9 ↗
5. 10.1146/annurev-cellbio-101512-12232610.1146/annurev-cellbio-101512-122326 ↗
6. 10.1016/j.canlet.2020.01.02310.1016/j.canlet.2020.01.023 ↗
7. 10.1126/science.aau697710.1126/science.aau6977 ↗
8. 10.1002/jev2.1203210.1002/jev2.12032 ↗
9. 10.1038/bjc.2017.18310.1038/bjc.2017.183 ↗
10. 10.2147/CMAR.S23238310.2147/CMAR.S232383 ↗
11. 10.1186/s13058-016-0753-x10.1186/s13058-016-0753-x ↗
12. 10.1158/1078-0432.CCR-14-236210.1158/1078-0432.CCR-14-2362 ↗
13. 10.1146/annurev.biochem.68.1.91310.1146/annurev.biochem.68.1.913 ↗
14. 10.1002/cam4.174110.1002/cam4.1741 ↗
15. 10.1007/s12032-023-01987-x10.1007/s12032-023-01987-x ↗
16. 10.1177/2192568223117359710.1177/21925682231173597 ↗
17. 10.1038/s41419-022-04510-810.1038/s41419-022-04510-8 ↗
18. 10.1038/s41598-021-88163-110.1038/s41598-021-88163-1 ↗
19. 10.1016/j.jprot.2012.12.02910.1016/j.jprot.2012.12.029 ↗
20. 10.1093/nar/gkr82810.1093/nar/gkr828 ↗
21. 10.1186/s13287-018-0923-010.1186/s13287-018-0923-0 ↗
22. 10.1080/20013078.2019.170324410.1080/20013078.2019.1703244 ↗
23. 10.1073/pnas.171892111510.1073/pnas.1718921115 ↗
24. 10.1074/mcp.M800337-MCP20010.1074/mcp.M800337-MCP200 ↗
25. 10.1016/j.immuni.2010.04.00510.1016/j.immuni.2010.04.005 ↗
26. 10.1074/jbc.M40002320010.1074/jbc.M400023200 ↗
27. 10.1091/mbc.e05-10-091510.1091/mbc.e05-10-0915 ↗
28. 10.1074/jbc.R113.47980810.1074/jbc.R113.479808 ↗
29. 10.1002/advs.20190051310.1002/advs.201900513 ↗
30. 10.1016/j.cyto.2018.02.00210.1016/j.cyto.2018.02.002 ↗
31. 10.1016/j.cmet.2021.09.00210.1016/j.cmet.2021.09.002 ↗
32. 10.1111/boc.20230000110.1111/boc.202300001 ↗
33. 10.1084/jem.190.12.184910.1084/jem.190.12.1849 ↗
34. 10.1016/j.cell.2014.03.05210.1016/j.cell.2014.03.052 ↗
35. 10.1038/s41586-023-06114-410.1038/s41586-023-06114-4 ↗
36. 10.1016/j.xpro.2024.10294310.1016/j.xpro.2024.102943 ↗
37. 10.1007/s00262-022-03187-410.1007/s00262-022-03187-4 ↗
38. 10.1038/s41598-019-51149-110.1038/s41598-019-51149-1 ↗
39. 10.1038/s41586-018-0392-810.1038/s41586-018-0392-8 ↗
40. 10.3389/fimmu.2024.139533210.3389/fimmu.2024.1395332 ↗
41. 10.3390/cancers1407180110.3390/cancers14071801 ↗
42. 10.1038/s41698-023-00418-410.1038/s41698-023-00418-4 ↗
43. 10.1016/j.jconrel.2022.09.04210.1016/j.jconrel.2022.09.042 ↗
44. 10.1038/s41598-023-35172-x10.1038/s41598-023-35172-x ↗
45. 10.1038/ncb200010.1038/ncb2000 ↗
46. 10.1016/j.cell.2015.05.02510.1016/j.cell.2015.05.025 ↗
47. 10.1158/1078-0432.CCR-08-019610.1158/1078-0432.CCR-08-0196 ↗
48. 10.1016/j.cell.2023.03.01010.1016/j.cell.2023.03.010 ↗
49. 10.1186/s12964-023-01413-910.1186/s12964-023-01413-9 ↗
50. 10.1126/sciadv.add394210.1126/sciadv.add3942 ↗
51. 10.3389/fgene.2018.0056110.3389/fgene.2018.00561 ↗
52. 10.1186/s12964-020-00607-910.1186/s12964-020-00607-9 ↗
53. 10.1038/bjc.2015.45010.1038/bjc.2015.450 ↗
54. 10.1038/s41568-021-00378-610.1038/s41568-021-00378-6 ↗
55. 10.1126/science.aaw547310.1126/science.aaw5473 ↗
56. 10.1016/j.celrep.2022.11060910.1016/j.celrep.2022.110609 ↗
57. 10.1016/j.cmet.2019.02.01610.1016/j.cmet.2019.02.016 ↗
58. 10.1016/j.jtho.2020.05.02210.1016/j.jtho.2020.05.022 ↗
59. 10.1158/1078-0432.CCR-20-196710.1158/1078-0432.CCR-20-1967 ↗
60. 10.1002/ctm2.72610.1002/ctm2.726 ↗
61. 10.1016/j.biopha.2021.11185810.1016/j.biopha.2021.111858 ↗
62. 10.1084/jem.2013191610.1084/jem.20131916 ↗
63. 10.1016/j.ccell.2016.10.01010.1016/j.ccell.2016.10.010 ↗
64. 10.3390/cancers1110147910.3390/cancers11101479 ↗
65. 10.1002/0471143030.cb0322s3010.1002/0471143030.cb0322s30 ↗
66. 10.1083/jcb.120.2.33910.1083/jcb.120.2.339 ↗
67. 10.1016/j.celrep.2021.10993410.1016/j.celrep.2021.109934 ↗
68. 10.1016/j.xpro.2022.10134010.1016/j.xpro.2022.101340 ↗
69. Gandin V. · J. Visualized Exp. · 2014 · 17
70. 10.1016/j.celrep.2021.10993410.1016/j.celrep.2021.109934 ↗
71. Ray A. · J. Visualized Exp. · 2010 · 28 · 1488
72. 10.1128/JVI.01353-1610.1128/JVI.01353-16 ↗
73. 10.1038/s42255-022-00636-310.1038/s42255-022-00636-3 ↗
74. 10.7554/eLife.1025010.7554/eLife.10250 ↗
75. 10.1038/s42255-020-0226-510.1038/s42255-020-0226-5 ↗